{"company":{"id":677155,"name":"Editas Medicine","domain":"editasmedicine.com","url":"https://alion.io/company/editasmedicine"},"section":"news","answer":"Editas Medicine: 7 headlines on record, 1 headline in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"7"},{"label":"In 90 days","value":"1"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":7},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-09-01","kind":"News","title":"Editas Medicine to Participate in Upcoming Investor Conferences","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/editas-medicine-to-participate-in-upcoming-investor-conferences-1036511342"},{"date":"2025-06-28","kind":"News","title":"Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?","source":"The Motley Fool","url":"https://fool.com/investing/2025/06/28/wall-street-expects-editas-medicine-to-soar-53-is/"},{"date":"2025-05-14","kind":"News","title":"Editas Medicine: A Cautionary Tale for Investors","source":"Nasdaq","url":"https://nasdaq.com/articles/editas-medicine-cautionary-tale-investors"},{"date":"2024-12-13","kind":"News","title":"Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026","source":"benzinga.com","url":"https://benzinga.com/general/biotech/24/12/42480865/editas-medicine-realigns-strategy-to-focus-on-in-vivo-gene-editing-targets-human-proof-of-concept-by-2026"},{"date":"2024-09-25","kind":"News","title":"Editas Medicine: A Risk/Reward Worth Considering","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4723252-editas-medicine-a-riskreward-worth-considering"},{"date":"2024-01-15","kind":"News","title":"Down 88%, Could Editas Medicine Be a Good Investment Now?","source":"The Motley Fool","url":"https://fool.com/investing/2024/01/15/down-88-could-editas-medicine-be-a-good-investment/"},{"date":"2016-01-05","kind":"News","title":"Editas Medicine (gene editing with CRISPR) files for IPO two years after founding","source":"sec.gov","url":"https://sec.gov/Archives/edgar/data/1650664/000104746916009534/a2226902zs-1.htm"}],"story":[{"title":"Team shrank to 109 was 294 · US Form 5500 (plan participants)"},{"title":"Founded"}],"as_of":"2026-11-15","cite":"Editas Medicine, News. Alion, Nov 15, 2026. https://alion.io/company/editasmedicine/news","html_url":"https://alion.io/company/editasmedicine/news","json_url":"https://alion.io/company/editasmedicine/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-15T01:00:43Z"}}